輝瑞支付3.45億美元結束腎上腺素注射針劑價格大升訴訟
美國藥廠輝瑞(PFE.US)及兩間子公司已同意3.45億美元的和解協議,結束有關腎上腺素注射針劑(EpiPen)價格大升的訴訟。
該訴訟可追溯到2016年,當時美國全國各地提出多個集體訴訟,指控上述公司從事與EpiPen相關的反競爭行爲。
EpiPen由輝瑞製造,當Mylan於2007年取得銷售及分銷權時,EpiPen的售價約100美元,而目前在沒有藥房優惠券或製造商折扣下,其售價超過650美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.